Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes.
Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, Kubonishi S, Morita Y, Nakashima Y, Onodera K, Suzuki K, Suzuki T, Tamai Y, Usuki K, Yokota A, Yonaga H, Hayakawa J, Midorikawa S, Nishio M, Suda M, Matsue K. Kosugi H, et al. Among authors: nishio m. Int J Hematol. 2024 Nov 21. doi: 10.1007/s12185-024-03872-3. Online ahead of print. Int J Hematol. 2024. PMID: 39572468
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
Akamatsu H, Koh Y, Nishio M, Goto Y, Hayashi H, Miura S, Tamada K, Kagamu H, Gemma A, Yoshino I, Misumi T, Mouri A, Saito R, Takase N, Yanagitani N, Nokihara H, Seike M, Takamura K, Mori M, Iwasawa S, Nakagawa S, Mitsudomi T. Akamatsu H, et al. Among authors: nishio m. Lung Cancer. 2024 Nov 9;198:108017. doi: 10.1016/j.lungcan.2024.108017. Online ahead of print. Lung Cancer. 2024. PMID: 39571250
Predictive Factors of Unexpected Hospitalization within Six Months of Undergoing Percutaneous Coronary Intervention in Patients with Chronic Coronary Disease.
Furukawa T, Mizote I, Shiraki T, Nakamura D, Nishio M, Fukushima N, Kitao T, Yokoi K, Kumada M, Kitagawa M, Nagai K, Kume K, Hirooka K, Nakagawa T, Ohama T, Takahara M, Hikoso S, Sakata Y. Furukawa T, et al. Among authors: nishio m. Intern Med. 2024 Nov 8. doi: 10.2169/internalmedicine.3929-24. Online ahead of print. Intern Med. 2024. PMID: 39523004 Free article.
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M. Tanaka H, et al. Among authors: nishio m. Eur J Cancer. 2024 Nov 5;213:115117. doi: 10.1016/j.ejca.2024.115117. Online ahead of print. Eur J Cancer. 2024. PMID: 39522333 Free article.
AREG Upregulation in Cancer Cells via Direct Interaction with Cancer-Associated Fibroblasts Promotes Esophageal Squamous Cell Carcinoma Progression Through EGFR-Erk/p38 MAPK Signaling.
Nakanishi T, Koma YI, Miyako S, Torigoe R, Yokoo H, Omori M, Yamanaka K, Ishihara N, Tsukamoto S, Kodama T, Nishio M, Shigeoka M, Yokozaki H, Kakeji Y. Nakanishi T, et al. Among authors: nishio m. Cells. 2024 Oct 19;13(20):1733. doi: 10.3390/cells13201733. Cells. 2024. PMID: 39451251 Free PMC article.
1,511 results